🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A promising phase 1 trial in patients with refractory #Hodgkinlymphoma underscores the potential value of allogeneic natural killer (NK) #celltherapy guided by NK cell-specific engagers. News & Views from Karl-Johan Malmberg, Ebba Sohlberg nature.com/articles/s4159…

Health impacts of exposure to synthetic chemicals in food: Our latest Review summarizes the sources, types & health effects of synthetic chemicals in foods (particularly #UPFs), and regulatory shortcomings & research needs. nature.com/articles/s4159…

Analysis of the phase 3 PRODROME trial reveals that treatment with# ubrogepant during the prodromal phase of #migraine may ameliorate common prodromal symptoms, with improvements as early as 1 hour after dose administration nature.com/articles/s4159…

Authors present results from the IMpower151 trial, they found the drug combination (which had previously been found to be effective in the Impower150 trial) was not significantly effective in a Chinese population. nature.com/articles/s4159…

🚨🥁Exciting Nature Medicine Publication Announcement 👉Hot off the press on this #ClinicalTrialsDay ! Thrilled to share our Nature Medicine paper: "Cancer treatment paradigms in the precision medicine era" 👉We propose 5 BOLD strategic recommendations to modernize cancer

Get your health boost Nature Medicine! Reporter anita makri talked to researchers Jameel Arts & Health Lab and elsewhere about using the arts (dance, music, singing) to support better health. Go here -> ow.ly/FBjO50VWtAn Dr Daisy Fancourt #artsinhealth

In a first-in-human Phase 1/2 study in 7 patients with #sicklecelldisease, autologous HSC lentiviral #genetherapy using reduced intensity conditioning was considered feasible and safe, achieving 80% reduction in vaso-occlusive events nature.com/articles/s4159…

We are recruiting! We are seeking a talented individual to join Nature Medicine’s international team to champion research in #AI, digital medicine and health informatics. The position is open for applicants in New York and Milan - deadline is May 30. springernature.wd3.myworkdayjobs.com/SpringerNature…

Post-hoc analysis of #ctDNA levels from patients with metastatic prostate cancer treated with [177Lu]Lu-PSMA-617 or cabazitaxel, low ctDNA levels were predictive of clinical benefit, and PTEN or ATM alterations were potential biomarkers of response. nature.com/articles/s4159…

Integrated analysis of the KRASG12C inhibitor sotorasib clinical efficacy biomarkers show that low expression of TTF-1 and high expression of NRF2 determine antitumor efficacy of sotorasib in non-small cell #lungcancer. #NSCLC nature.com/articles/s4159…

⚡Our May issue is out! Our #Futureofmedicine theme is food and nutrition (see our editorial and 2 reviews); we also have News, Opinion and new research on #airpollution, #aging, #diets, #ctDNA, #mpox, #HIV, #glioblastoma, #Alzheimersdisease & much more! nature.com/nm/volumes/31/…

⭐Research highlight: A modeling study predicts a resurgence of previously eliminated infectious diseases if current child #vaccination rates continue to fall — with #measles being the first to reach endemic levels. JAMA nature.com/articles/d4159…

⭐Research highlight: Three studies reveal elevated mitochondrial metabolism as a driver of #clonalhematopoiesis and suggest that targeting the former — for example, with metformin — could reduce the risk of associated diseases. nature.com/articles/d4159…

New Review on #PrecisionNutrition Marta Gausch Ferre, Jordi Merino & colleagues critically examine the evidence, the challenges in translating short-term studies into long-term clinical effectiveness, and opportunities ahead University of Copenhagen Research Novo Nordisk Foundation nature.com/articles/s4159…

In a prospective study of asymptomatic individuals with average risk for cancer, a #multicancer early-detection test based on plasma cell-free DNA genomics and fragmentomics showed encouraging accuracy in identifying ongoing disease and tissue of origin. nature.com/articles/s4159…

⭐Research highlight: In a phase 2 trial, complete responses to #neoadjuvant #dostarlimab allowed most patients with early-stage mismatch repair-deficient solid tumors to avoid surgery, allowing preservation of affected organs. NEJM nature.com/articles/d4159…

In the Tumor Profiler proof-of-concept observational study, a #multiomics approach for profiling tumors from patients with #melanoma was feasible, returning data within four weeks and informing treatment recommendations in 75% of cases. nature.com/articles/s4159…

As presented at #ASCO25: In the phase 2 TUXEDO-3 trial, patients with leptomeningeal metastatic disease from any solid tumor had encouraging 3 month overall survival after treatment with the HER3-targeting antibody-drug conjugate patritumab deruxtecan nature.com/articles/s4159…

As presented at #ASCO25: In the phase 3 CREST trial, the combination of subcutaneous sasanlimab, an anti-PD-1 inhibitor, with BCG induction and maintenance treatment significantly improved event-free survival vs. standard of care therapy nature.com/articles/s4159…

As presented at #ASCO25: In the phase 2 NeoCOAST-2 platform trial, neoadjuvant durvalumab + chemotherapy + a TROP2-targeting antibody-drug conjugate led to a high pathologic complete response rate in patients with resectable non-small cell #LungCancer nature.com/articles/s4159…